Startups · Amsterdam, Netherlands

VectorY Therapeutics

a gene therapy that lets nerve cells make their own antibody against ALS

Website · Sector: Health

From our lists 15 new startups in Amsterdam worth knowing (2026) and Dutch startups to know: 25 new startups in the Netherlands (2026)

VectorY develops VTx-002, an experimental gene therapy for ALS: a harmless virus delivers the instructions for an antibody to nerve cells, which then make the antibody themselves, aimed at TDP-43, a protein that forms toxic clumps in people with ALS; it is being tested in the PIONEER-ALS trial and has not been approved by any regulator. Founded in August 2020 at Amsterdam Science Park by Carlo Incerti, Pavlina Konstantinova, Anthony Newcombe and Barbara Sanders with seed funding from Forbion, it raised 74.5 million euro with new investors Angelini Ventures, the European Investment Bank and Invest-NL (7 million euro) and existing investors including Forbion, EQT Life Sciences, Insight Partners and Eli Lilly, as IO+ reported on 12 November 2026. Website: vectorytx.com. Source: IO+, Business Wire.

Questions about VectorY Therapeutics

What does VectorY Therapeutics do?

VectorY Therapeutics: a gene therapy that lets nerve cells make their own antibody against ALS.

Where is VectorY Therapeutics based?

VectorY Therapeutics is based in Amsterdam, Netherlands.

Where can I read more about VectorY Therapeutics?

VectorY Therapeutics is in our list 15 new startups in Amsterdam worth knowing (2026): https://meetnewbrands.com/articles/new-startups-in-amsterdam-2026

Is this your startup?Get a free founder story written with you, or add your latest funding round. Something out of date? Tell us.Pitch your story